Journal of VitreoRetinal Diseases最新文献

{"title":"Long-Term Follow-up of Cytomegalovirus Retinitis in an Immunocompetent Patient.","authors":"Michael J Maywood, Lisa J Faia, Tedi Begaj","doi":"10.1177/24741264251338042","DOIUrl":"https://doi.org/10.1177/24741264251338042","url":null,"abstract":"<p><p><b>Purpose:</b> To describe the long-term follow-up of an immunocompetent patient with cytomegalovirus (CMV) retinitis. <b>Methods:</b> A single case was analyzed and a literature review performed. <b>Results:</b> A 47-year-old woman presented with a paracentral scotoma in the left eye. Examination showed parafoveal retinitis. An aqueous fluid tap was positive for CMV on polymerase chain reaction; however, there was no recent surgery or local or systemic immunosuppression. A thorough workup, including pan imaging, was unremarkable. The retinitis resolved with oral valganciclovir and adjuvant intravitreal ganciclovir and foscarnet injections. At the 3-year follow-up, the patient's disease was inactive without development of systemic illness. <b>Conclusions:</b> In patients presenting with retinitis, the diagnostic use of aqueous polymerase chain reaction is critical, especially in atypical cases in which the retinitis might be associated with CMV.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251338042"},"PeriodicalIF":0.5,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wavefront Aberrometry in Pseudophakic Patients Before and After Vitrectomy for Bothersome Floaters.","authors":"Daniel A Adelberg, Mark T Parsons","doi":"10.1177/24741264251333200","DOIUrl":"https://doi.org/10.1177/24741264251333200","url":null,"abstract":"<p><p><b>Introduction:</b> To investigate whether the outcome of patients with persistent bothersome floaters who are managed with vitrectomy can be correlated with improvements in higher-order aberrations with wavefront aberrometry. <b>Methods:</b> Pseudophakic patients who had 27-gauge vitrectomy for persistent floaters and whose clinical assessment included preoperative and postoperative wavefront aberrometry were included. The primary outcome was the change in the higher-order aberration percentage measured by wavefront aberrometry. <b>Results:</b> The study included 76 eyes of 66 patients with a mean age (±SD) of 67.8 ± 7.5 years. The Snellen visual acuity improved from 20/32 preoperatively to 20/25 postoperatively (<i>P</i> = .004). Wavefront aberrometry showed a highly significant reduction in the higher-order aberration percentage (<i>P</i> < .000001), with a mean preoperative percentage of 53.9 and a mean postoperative percentage of 38.3. Subgroup analysis found a significant reduction in patients with no previous posterior capsulotomy (<i>P</i> = .001), previous neodymium:YAG capsulotomy (<i>P</i> < .000001), a monofocal intraocular lens (IOL) (<i>P</i> < .000001), and a multifocal IOL (<i>P</i> = .006). There was no significant difference in the mean preoperative and postoperative pupil size, sphere, cylinder, or spherical equivalent. <b>Conclusions:</b> Wavefront aberrometry demonstrates an objective, significant reduction in higher-order aberrations immediately after vitrectomy in pseudophakic patients with bothersome floaters.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251333200"},"PeriodicalIF":0.5,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bullous Central Serous Chorioretinopathy Associated With JAK Inhibitor Use.","authors":"Warren Apel, Ye Li","doi":"10.1177/24741264251337104","DOIUrl":"https://doi.org/10.1177/24741264251337104","url":null,"abstract":"<p><p><b>Purpose:</b> To report a case of bullous central serous chorioretinopathy (CSCR) after starting a Janus kinase (JAK) inhibitor and describe the results of focal laser treatment. <b>Methods:</b> A single case was evaluated. <b>Results:</b> A 54-year-old man with rheumatoid arthritis presented with a 2-week history of left superior field loss. His medications included prednisone 10 mg and upadacitinib, which was added to his regimen 3 weeks previously. His visual acuity (VA) was 20/25 OD and 20/30 OS. An ophthalmic examination of the left eye found an ill-defined white lesion of 2 × 3 disc diameters at the macula with an inferior retinal detachment (RD). Optical coherence tomography showed subretinal fibrin with subretinal fluid (SRF) and a pigment epithelial detachment. After a diagnosis of bullous CSCR was made, focal laser application was performed. One year later, the patient's VA recovered to 20/20 with resolved SRF. <b>Conclusions:</b> Bullous CSCR with a serous RD is an uncommon subtype of pachychoroid disease. Upadacitinib may be associated with its occurrence through disequilibrium of the coagulation cascade. Focal laser treatment offers a favorable outcome for this disease.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251337104"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-Associated Retinopathy Presenting as Panuveitis Secondary to Minimally Invasive Follicular Thyroid Carcinoma.","authors":"Natalie Arnold, Amit Mishra, Mark Seamone","doi":"10.1177/24741264251337108","DOIUrl":"https://doi.org/10.1177/24741264251337108","url":null,"abstract":"<p><p><b>Purpose:</b> To describe a case of cancer-associated retinopathy (CAR) secondary to follicular thyroid carcinoma. <b>Methods:</b> A single retrospective case was evaluated. <b>Results:</b> A 68-year-old woman presented with floaters and decreased vision in the right eye and was found to have panuveitis. The left eye subsequently developed panuveitis 6 months later, ultimately resulting in retinal atrophy. Extensive investigations, including vitreous biopsies, imaging, and positron emission tomography, led to a diagnosis of CAR secondary to minimally invasive follicular thyroid carcinoma with serology positive for anti-enolase, anti-HSP60, and anti-glyceraldehyde-3-phosphate dehydrogenase. <b>Conclusions:</b> Cases of CAR secondary to minimally invasive follicular thyroid carcinoma are rare. Ensuring an early diagnosis and promptly initiating treatment, with a goal of preserving sight, are imperative.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251337108"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal Aflibercept With vs Without Pneumatic Displacement for Submacular Hemorrhage Associated With Polypoidal Choroidal Vasculopathy.","authors":"Taku Wakabayashi, Chikako Hara, Akihiko Shiraki, Nobuhiko Shiraki, Yoko Fukushima, Susumu Sakimoto, Kaori Sayanagi, Kentaro Nishida, Shigeru Sato, Hirokazu Sakaguchi, Kohji Nishida","doi":"10.1177/24741264251335629","DOIUrl":"https://doi.org/10.1177/24741264251335629","url":null,"abstract":"<p><p><b>Purpose:</b> To compare the visual outcomes of intravitreal (IVT) aflibercept with pneumatic displacement vs without pneumatic displacement for submacular hemorrhage (SMH) associated with polypoidal choroidal vasculopathy (PCV). <b>Methods:</b> This retrospective study assessed patients with SMH associated with PCV who were treated with aflibercept and pneumatic displacement with gas (aflibercept+gas group) or with aflibercept alone (monotherapy group). Patients were followed for at least 12 months, with the best-corrected visual acuity (BCVA) at 12 months the primary outcome measure. <b>Results:</b> Forty-seven eyes of 47 patients were retrospectively analyzed from August 2013 to March 2023. The aflibercept+gas group comprised 25 eyes and the monotherapy group, 22 eyes. The 2 groups had comparable baseline characteristics. The mean logMAR best-corrected visual acuity (BCVA) before treatment was 0.78 ± 0.46 in the aflibercept+gas group and 0.83 ± 0.66 in the monotherapy group (<i>P</i> = .76). The mean BCVA (0.26 ± 0.42 vs 0.85 ± 0.57) and the mean change in (-0.52 ± 0.55 vs 0.02 ± 0.75) 12 months postoperatively was significantly better in the aflibercept+gas group than in the monotherapy group (<i>P</i> < .001 and <i>P</i> < .008, respectively). The BCVA improved by 3 or more lines in 60.0% of eyes in the aflibercept+gas group but in only 18.2% of eyes in the monotherapy group. Vitreous hemorrhage developed in 16.0% of eyes in the aflibercept+gas group and in 13.6% of eyes in the monotherapy group and retinal detachment in 4.0% and 0%, respectively (both <i>P</i> = 1.000). <b>Conclusions:</b> Better visual outcomes were achieved with IVT aflibercept and pneumatic displacement than with aflibercept alone for SMH associated with PCV.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251335629"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Treatment in Patients With Small and Medium-Small Class 2 Gene Expression Profiling Uveal Melanoma to Reduce Mortality.","authors":"Natalia C González, Victor M Villegas, Aaron S Gold, Azeema Latiff, Timothy G Murray","doi":"10.1177/24741264251337101","DOIUrl":"https://doi.org/10.1177/24741264251337101","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the class 2 gene expression profiling of patients with small and medium-small uveal melanoma, focusing on tumor control, metastases, and mortality. <b>Methods:</b> This retrospective case series evaluated patients treated for small or medium-small uveal melanoma by the same surgeon. Patients with small uveal melanoma were treated with microincision vitrectomy surgery or brachytherapy, and patients with medium-small uveal melanoma were treated with brachytherapy. All patients were gene expression profiling class 2. <b>Results:</b> Forty-two patients (21 with a diagnosis of small melanoma; 21 with a diagnosis of medium-small melanoma) with a mean age of 58 years and a confirmed diagnosis of class 2 gene expression profiling melanoma were identified. The melanoma-specific mortality at the 5-year follow-up was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. The rate of melanoma-specific active metastasis at 5 years was 4.8% (1/21) for patients with small melanoma and 14.3% (3/21) for patients with medium-small melanoma. In both groups, the enucleation rate at 5 years was 0%. <b>Conclusions:</b> Small tumor management achieves excellent anatomic and visual outcomes but mandates diagnostic accuracy and defined long-term outcomes as well as follow-up (5-year minimum in this series). Gene expression profiling classification is important in prognostication; however, early treatment of small tumors significantly decreases the predicted mortality and has the greatest potential effect on patient survival, even for class 2 melanomas.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251337101"},"PeriodicalIF":0.5,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12031732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Sterile Granulomatous Uveitis Caused by Intravitreal Injections of Faricimab.","authors":"Christine Hill, Dimitrios C Arhontoulis, Huyen Bui, Sarah M DeVaro, Peter H Tang","doi":"10.1177/24741264251330339","DOIUrl":"https://doi.org/10.1177/24741264251330339","url":null,"abstract":"<p><p><b>Purpose:</b> To describe a case of severe bilateral granulomatous uveitis caused by treatment with faricimab. <b>Methods:</b> A single case was reviewed. <b>Results:</b> A 79-year-old woman with diabetic macular edema developed severe uveitis OU 16 days after bilateral intravitreal (IVT) injections of faricimab. The patient's visual acuity (VA) was hand motions OD and 20/400 OS. She refused IVT antibiotics at bedside but consented to an emergency pars plana vitrectomy (PPV) OU. The laboratory workup for infectious and autoimmune etiologies was unremarkable, as were bacterial and fungal cultures from the PPV. High-dose systemic steroids were initiated after surgery. The patient's VA recovered to 20/30 OD and 20/25 OS. <b>Conclusions:</b> Reports of severe uveitis resulting from injections of faricimab have been documented. We describe a unique case in which the patient with granulomatous uveitis OU experienced a significant decline in vision. With high-dose systemic steroid therapy and surgical intervention, her VA recovered to near baseline.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330339"},"PeriodicalIF":0.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD.","authors":"Marta Stevanovic, Nicole Koulisis, Tom Chen, Stavros N Moysidis, Bruce Burkemper, Brian C Toy, Narsing A Rao, Dean Eliott, Mark S Humayun","doi":"10.1177/24741264251332515","DOIUrl":"10.1177/24741264251332515","url":null,"abstract":"<p><p><b>Purpose:</b> To compare the rates of intraocular inflammation (IOI) in patients with neovascular age-related macular degeneration (nAMD) after injection of intravitreal (IVT) antivascular endothelial growth factor drugs. <b>Methods:</b> This study included all phase 3 randomized clinical trials of patients with nAMD treated with ranibizumab, aflibercept, brolucizumab, abicipar pegol, or faricimab. The outcomes assessed were the incidence of IOI, retinal artery occlusion (RAO), retinal vasculitis and choroiditis, endophthalmitis, and serious systemic adverse events (AEs) as well as the change in visual acuity (VA) (Early Treatment Diabetic Retinopathy Study letters) and in central retinal thickness (CRT). <b>Results:</b> Abicipar pegol was associated with a higher incidence of IOI than aflibercept, ranibizumab, faricimab, and sham injections, while brolucizumab was associated with a higher rate of IOI than aflibercept, faricimab, and sham injections. Abicipar pegol was also associated with a higher rate of endophthalmitis than aflibercept. Significantly more retinal vasculitis and choroiditis was seen with abicipar pegol and brolucizumab than with ranibizumab and aflibercept, respectively, and RAOs occurred more frequently with abicipar pegol and brolucizumab than with ranibizumab and aflibercept, respectively. There were no differences in the change in VA among the drugs. Treatment with brolucizumab resulted in a greater change in CRT than with abicipar pegol, aflibercept, ranibizumab, and faricimab, while treatment with faricimab resulted in a greater change in CRT than aflibercept and ranibizumab. Faricimab was associated with fewer serious systemic AEs than aflibercept. <b>Conclusions:</b> Abicipar pegol and brolucizumab were associated with a higher incidence of ocular AEs in phase 3 randomized controlled trials. The potential benefits of these drugs should be weighed against the AEs.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251332515"},"PeriodicalIF":0.5,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144042611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peer-Review Essentials: Reviewing Manuscripts for the <i>Journal of VitreoRetinal Diseases</i>.","authors":"Eric Jung, Aleksandra Rachitskaya, Yoshihiro Yonekawa, Timothy G Murray","doi":"10.1177/24741264251331647","DOIUrl":"https://doi.org/10.1177/24741264251331647","url":null,"abstract":"<p><p>The thoughtful process of peer review allows for the vetting and improvement of scientific work that leads to quality research and, eventually, advancement of the field of retina. Progress in medicine would not occur without dedicated researchers, but just as important are the peer reviewers who take the time assess their work, weigh in on their validity, and help bring these papers to life. Here, we discuss how to effectively review a journal manuscript in a way that helps both the beginning reviewer and the seasoned expert develop a framework to provide meaningful peer review. Although this guide was specifically written with <i>JVRD</i> aims in mind, these suggestions can be broadly applied to the process of manuscript review in general.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251331647"},"PeriodicalIF":0.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Successive Branch Retinal Artery Occlusions in a Patient With Antiphospholipid Syndrome Despite Anticoagulation.","authors":"Samantha R Goldburg, Albert S Li","doi":"10.1177/24741264251331638","DOIUrl":"https://doi.org/10.1177/24741264251331638","url":null,"abstract":"<p><p><b>Purpose:</b> To describe a patient with antiphospholipid syndrome presenting with branch retinal artery occlusions (BRAO) despite anticoagulation. <b>Methods:</b> A single case was evaluated. <b>Results:</b> A 53-year-old woman with antiphospholipid syndrome on anticoagulation presented for a routine ophthalmic examination. She had no visual complaints, and the visual acuity was 20/25^-1 OD and 20/30^-1 OS. A BRAO was found in the right eye. Despite treatment with aspirin, warfarin, prednisone, plasmapheresis, and rituximab, multiple new occlusions were found when the patient returned the next month. She ultimately had a stroke, which led to her death. <b>Conclusions:</b> This case underscores the importance of interdisciplinary care for patients with antiphospholipid syndrome presenting with BRAOs despite anticoagulation.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251331638"},"PeriodicalIF":0.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}